Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| K12RR017665 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Center for Research Resources (NCRR) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A growing number of people in this country are overweight or obese. This is concerning as increasing weight has been shown to increase the risk of developing heart failure. However, there is also research to suggest that in people who already have heart failure, heavier people live longer. So, how does being overweight put a person at risk for heart failure, but once they have heart failure, protect them? There is no clear explanation for this dilemma.
People who are obese commonly have other diseases, such as high blood pressure, high cholesterol, and diabetes, that increase the risk of developing heart disease. It is this group of diseases that is referred to as "The Metabolic Syndrome." People with the metabolic syndrome also have increased levels of inflammation and clotting proteins in their blood stream. Current treatment of the metabolic syndrome involves using medications for cholesterol, blood pressure, and diabetes. Diet and exercise are also commonly recommended.
"Lifestyle intervention programs" are programs that help people lose weight by changing their eating habits and exercise / activity routines. Weight loss and exercise have been shown to lower the risk of developing diabetes and improve diabetes control, improve cholesterol abnormalities, and lower blood pressure. These programs have not previously included heart failure patients, however.
We hypothesize that using a lifestyle intervention program in addition to the usual medications for heart failure will result in improved symptoms of heart failure and control of the metabolic syndrome.
This study will be the first research study to look at the use of diet and exercise in treating heart failure patients who are overweight / obese with "the metabolic syndrome." The study will last 6 months. From this study we hope to learn whether diet and exercise is helpful in treating heart failure patients who are overweight. Specifically, the study will look at the short term effects on cardiac risk factors (blood pressure, cholesterol, blood sugar), heart failure symptoms, and exercise capacity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | Patients continue receive a single educational session and continue medical managment of heart failure as per their physician | |
| Lifestyle modification | Experimental | Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lifestyle Modification (diet, exercise, and behavior) | Behavioral | Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program. |
| Measure | Description | Time Frame |
|---|---|---|
| Measuring the change in Flow Mediated Dilation (FMD) and flow velocity integral (FVI) to assess endothelial function. | 6 months | |
| Correlating change in vascular reactivity with renin, angiotensin II, and aldosterone levels. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Examining the impact of the lifestyle interventions on quality of life as measured by the validated Kansas City Cardiomyopathy Questionnaire. | 3 and 6 months | |
| Assessing the effectiveness of the lifestyle intervention by sequential tracking of the weekly minutes of physical activity and body composition parameters. Overall exercise tolerance will be assessed using the 6 minute walk test. |
Not provided
Inclusion Criteria:
Must meet 3 or more of the NCEP defined criteria for metabolic syndrome
Individuals with heart failure of ischemic or nonischemic etiologies * NYHA class II - III symptoms
Left ventricular ejection fraction less than 40%
Age 18-75 years
BMI greater than 25 kg/m2
Patients must have undergone a VO2 or exercise stress test within the last 6 months to exclude active ischemia or exercise-induced dysrhythmias
Exclusion Criteria:
NYHA IV or 6 minute walk less than 300 meters
Blood pressure greater than 160/100 mmHg
Patients undergoing active titration of their cardiac medications
Other comorbid illnesses which limit expected lifespan or affect the safety of interventions
Weight loss of more than 10 pounds of non-edematous body weight within the past 3 months
Pregnancy
HIV+, active tuberculosis or hepatitis C
Cancer requiring treatment within the past 5 years, unless the prognosis is excellent
Unstable angina, myocardial infarction, coronary artery bypass surgery, or angioplasty within the last 3 months
Angina with exertion
History of malignant arrythmias (Ventricular Tachycardia / Ventricular Fibrillation) without implanted defibrillator
Valvular heart disease:
Hypertrophic cardiomyopathy
Severe pulmonary hypertension with a pulmonary artery systolic pressure > 60 mmHg -
Aortic aneurysm (>6 cm in diameter)
Factors that may limit adherence to interventions or affect conduct of the trial
History of bariatric surgery
Chronic treatment with corticosteroids
Current diagnosis of schizophrenia, other psychotic disorder, or bipolar disorder
Current use of medications for weight loss
Inability to walk two blocks
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Allison M. Pritchett, M.D. | Baylor College of Medicine | Principal Investigator |
| Douglas L Mann, M.D. | Baylor College of Medicine | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D024821 | Metabolic Syndrome |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
Not provided
Not provided
| ID | Term |
|---|---|
| D004032 | Diet |
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009747 | Nutritional Physiological Phenomena |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D009043 | Motor Activity |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 and 6 months |
| Defining alterations in metabolic syndrome parameters, inflammatory cytokines and platelet activation. | 3 and 6 months |
| D044882 |
| Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |